FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Gastroenterologist Dr Salhab warns that liver cirrhosis can lead to overt hepatic encephalopathy, impacting brain function ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Cirrhosis can be a serious diagnosis, but it’s not an automatic death sentence. Around 57% of patients with cirrhosis die from liver-related causes [10], but many others live for years ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

Cirrhosis or fibrosis of the liver can occur due to several liver-related diseases and conditions, such as hepatitis, non-alcoholic fatty liver disease, and excessive alcohol consumption.

Men with cirrhosis have a significantly higher risk for liver-related complications ― particularly hepatocellular carcinoma ― ...

Cirrhosis is also associated with an enlarged spleen that may entrap platelets, the blood cells involved in clotting; so measuring a person's platelet count can be useful in diagnosing the liver ...